Apnimed, Inc. 424B4final IPO prospectus

Executive Summary

Apnimed is a late-stage pharmaceutical company betting on Oxnimbi, a once-nightly oral treatment for obstructive sleep apnea; future economics depend on drug sales, while current revenue comes entirely from its Shionogi/SASS collaboration. FY2025 revenue rose 380% to $38.5M, but net loss reached $(128)M; Q1 2026’s $67.7M profit principally reflects a $74.8M revenue-accounting adjustment, not commercial traction. The $192M all-primary IPO values the company at an implied $637M, with buyers receiving 30.1% of outstanding shares before equity-award dilution. At $16.00, investors are buying a concentrated approval-and-launch opportunity: positive respiratory endpoints support the case, but FDA questions about clinical meaningfulness and substantial treatment discontinuation challenge its conversion into durable sales.

The Offering

• Size and implied valuation: 12.0M shares at $16.00 → $192M gross proceeds, $637M market capitalization on 39,823,183 post-IPO shares, 30.1% buyer ownership and 16.6× FY2025 revenue. Including outstanding options, subsequent grants, lender warrants and IPO option grants gives 50,648,602 fully diluted shares, $810M capitalization and 23.7% buyer ownership, without crediting exercise proceeds; remaining plan reserves could dilute further.
• Structure and listing: all shares are primary, so proceeds go to Apnimed rather than selling holders. Estimated net proceeds: ≈$174M; the 30-day, 1.8M-share underwriters’ option raises gross proceeds to $221M and estimated net proceeds to ≈$200M. Lead representatives: BofA Securities, Evercore and Cantor Fitzgerald; Nasdaq Global Select Market ticker: APMD.
• Use of proceeds: ≈$238M, combining IPO proceeds and existing cash, for Oxnimbi’s regulatory process and launch if approved; remaining funds support R&D, working capital and general purposes. Management projects funding through 6/2028, making existing resources essential because the Oxnimbi allocation exceeds IPO net proceeds.
• Per-share backing: each $16.00 share is backed by $7.45 of net tangible assets after the IPO—a $8.55 gap. Existing holders paid an average $11.56 per share; with the option fully exercised, tangible backing rises to $7.77.
• Capitalization bridge: “after IPO” assumes security conversions, April’s SASS sale and term-loan financing, and the offering. Cash moves from $46.9M before these transactions → $193M before offering proceeds → $368M after IPO; equity moves from $(304)M → $123M → $297M. The bridge includes $100M sale proceeds, $46.1M net loan funding, conversion of preferred stock and notes, and transaction-related gains.
• Timing and resale: prospectus dated 7/30/2026; delivery expected on or about 8/3/2026. Substantially all 27.8M restricted shares face a 180-day lock-up ending 1/26/2027, subject to early waiver and subsequent resale restrictions; that overhang exceeds twice the initial IPO float.

Key Financial Highlights

$M; historical figures unless labeled otherwise. Balance sheets are period-end.

• Revenue quality: the $74.8M Q1 catch-up followed revised estimates of remaining collaboration-service costs; without it, management reports a $(7.1)M quarterly loss. April’s separate $57.1M deposit release is other income, not Q1 revenue.
• Cash divergence: recognizing previously deferred revenue generated accounting income without equivalent new cash receipts; deferred revenue fell $82.7M while operations still consumed cash.
• Expense trajectory: pivotal-trial completion reduced R&D, narrowing operating losses; launch preparation, manufacturing, marketing and public-company costs are expected to increase spending.
• Annual loss distortion: FY2025 discontinued-operations losses included $62.2M from Apnimed’s share of SASS’s contributed R&D write-off. April’s disposal separately produces an illustrative $85.6M gain, not recurring earnings.
• Negative equity: the $330M accumulated deficit reduces equity, while $246M of convertible preferred stock sits outside it until conversion. Total liabilities of $137M versus $38.5M debt show the deficit is not principally borrowing.
• Liquidity: preliminary, unaudited 6/30/2026 cash was ≈$173M. Historical statements carry going-concern doubt; the offering strengthens funding but does not establish profitability or eliminate future financing needs.

Business Model and Growth Drivers

Oxnimbi combines aroxybutynin and atomoxetine to improve upper-airway muscle activity. Apnimed expects no product-sales revenue before 2027, contingent on approval; historical revenue is concentrated entirely in Shionogi/SASS services.

Phase 3 trials enrolled 1,265 adults. At week 26, apnea-hypopnea index—the frequency of breathing interruptions—fell 44.1% vs 17.6% on placebo in SynAIRgy and 33.7% vs 7.3% in LunAIRo under analyses including treatment discontinuation. These respiratory improvements support efficacy, but cardiovascular benefits remain modeled rather than demonstrated outcomes.

Management targets ≈10.5M diagnosed but untreated U.S. patients, planning 125–150 sales representatives covering 15,000–20,000 clinicians. Oral convenience could reach patients poorly served by positive airway pressure, but surveys do not establish prescriptions, reimbursement or persistence. Apnimed owns no manufacturing facilities, and commercial active-ingredient supply agreements remain unsigned.

April’s $100M SASS sale refocuses resources on Oxnimbi; a possible $50M milestone and sales earnouts provide contingent upside, alongside transition services through 2026–2027.

Governance and Control

• Ownership: post-IPO shares become one common class; Alpha Wave holds 17.7%, Morningside 17.4%, Columbia 10.8% and Shionogi 7.42%, absent additional purchases. Concentration preserves significant incumbent influence without a disclosed majority holder.
• Oversight: five of seven directors are independent; special investor board-election rights terminate at closing. A staggered board, restricted director removal and limits on stockholder action make control changes harder.
• Leadership and incentives: Kevin Lind became chief executive in 6/2026, replacing founder Lawrence Miller. IPO-related options cover 1.11M shares; Lind also has a scheduled 1.1%-of-fully-diluted-equity grant in Q1 2027, while annual plan increases permit continuing dilution.
• Related parties: Shionogi is both a major holder and the collaboration counterparty/SASS buyer; board or audit-committee review governs qualifying transactions, but financing and commercial relationships remain intertwined.

Risk Assessment

• Audit and controls: unresolved financial-reporting material weakness and historical going-concern doubt raise reporting and financing risk, particularly given estimate-sensitive collaboration revenue.
• Approval concentration: Oxnimbi is the sole clinical candidate, and FDA questions about clinical meaningfulness could result in additional studies, delayed approval or restrictive labeling.
• Adoption and tolerability: six-month adverse-event discontinuation reached 21.2% and 23.7% vs 3.1% and 6.6% on placebo, threatening persistence despite respiratory efficacy; reimbursement and competing treatments further constrain uptake.
• Secured financing: $50M drawn debt carries benchmark interest plus 5.75%, revenue-linked payments and a $20M controlled-cash minimum; additional tranches require approval and sales milestones, while substantially all assets secure repayment.
• Supply and licensed rights: outsourced manufacturing, unsigned commercial ingredient contracts and dependence on the Brigham and Women’s Hospital license could interrupt approval, launch or commercialization.
• Valuation and dilution: 16.6× collaboration revenue is not a product-sales valuation benchmark; the $637M basic valuation requires successful approval and durable sales, with awards and post-lock-up selling increasing share-supply risk.

Investor Actionables

The investment case requires Oxnimbi’s respiratory efficacy to translate into an approvable label and sustained reimbursed use. Proceeds fund regulatory work and launch—not an already proven commercial franchise.

• Regulatory outcome: at the FDA’s 2/28/2027 goal date, assess whether the decision resolves clinical-meaningfulness concerns; approval with a commercially usable label supports the case, while extra trials or restrictive labeling undermine it.
• Patient persistence: starting from 21.2%–23.7% six-month adverse-event discontinuation, subsequent clinical and safety disclosures should show manageable tolerability; persistent discontinuation or new safety restrictions would weaken adoption.
• Launch execution: test the planned 125–150-representative launch and supply readiness against later product-sales and market-access disclosures; functioning supply and growing sales support execution, while delays or constrained coverage refute it.
• Funding durability: test management’s 6/2028 runway against cash use and deployment of ≈$238M toward Oxnimbi; adequate funding through launch supports the plan, while earlier refinancing or spending redirection weakens it.